Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INMT | O95050 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984828 | 0.78 | CYP2D6 (0.36) | — | |
| SCHEMBL11982462 | 0.73 | INMT (0.43) | INMT | |
| SCHEMBL14344950 | 0.66 | — | — | |
| SCHEMBL329869 | 0.59 | F2 (0.45) | INMT | |
| Phosphoric Acid SCHEMBL30540294 | 0.58 | — | — | |
| SCHEMBL19379300 | 0.58 | BRD4 (0.30) | — | |
| SCHEMBL11759308 | 0.56 | POLB (0.40) | — | |
| SCHEMBL9815040 | 0.56 | L3MBTL1 (0.40) | INMT | |
| SCHEMBL24052062 | 0.54 | INMT (0.31) | INMT | |
| SCHEMBL8740911 | 0.54 | INMT (0.33) | INMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | WASHINGTON UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20210393563-A1 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-23 | — | — | US | disclosed |
| US-9434753-B2 | Modified creatine compounds | GENCIA CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150005258-A1 | Modified Creatine Compounds | Genci Corporation (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140045798-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | GENCIA CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130072462-A1 | Mitochondrial Compositions and Uses Thereof | GENCIA CORPORATION (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | AVICENA GROUP, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100329997-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045798-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | CS, UQCRC1, UQCRC2 | INMT 2619/4885 |
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | PC, CKMT1A; CKMT1B, CHEK1 | INMT 3471/4885 |
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | PC, CKMT1A; CKMT1B, CHEK1 | INMT 3471/4885 |
| US-20100329997-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | INMT 3471/4885 |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | INMT 3471/4885 |
| US-20210393563-A1 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | CHRNB2, PSEN2, CX3CR1 | INMT 2643/4885 |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | INMT 3471/4885 |
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | CX3CR1, CD68, FYN | INMT 2721/4885 |
| US-20130072462-A1 | Mitochondrial Compositions and Uses Thereof | UQCRC1, CS, UQCRC2 | INMT 2820/4885 |
| US-20150005258-A1 | Modified Creatine Compounds | CKMT1A; CKMT1B, SLC25A20, ARG2 | INMT 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.